Non-Hodgkin lymphoma

Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer

Retrieved on: 
Thursday, April 20, 2023
Executive, Senior, Engineering, Non-Hodgkin lymphoma, University of Tulsa, Cancer, Timothy, Cerus Corporation, Organization, CAR, Kite Pharma, Patient, Risk, SAN, Engineering management, FDA, Therapy, Chemical engineering, Pharmaceutical industry, EU, Genentech, Allogeneic processed thymus tissue, Northwestern University

SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.
  • Mr. Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.
  • Once again, we both look forward to bringing to patients the next generation CAR T,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
  • Most recently, he continued his effort of advancing the field of engineered cell manufacturing as Chief Operating Officer of Instil Bio, and President and Chief Operating Officer of PACT Pharma.

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Thursday, April 20, 2023
Immortalised cell line, Abstract, AACR, Follicular lymphoma, Multiple myeloma, Venetoclax, Non-Hodgkin lymphoma, Lenalidomide, NHL, American Association for Cancer Research, Bortezomib, Patient, Apoptosis, Poster, Pharmaceutical industry, Vaccine, Salinicola salarius

HOUSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced the presentation of two posters related to the company’s novel molecular glue, SP-3164, at the American Association for Cancer Research (AACR) Annual Meeting. Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).

Key Points: 
  • Both abstracts highlight preclinical findings with SP-3164, with one focused on non-Hodgkin lymphoma (NHL) and the other on multiple myeloma (MM).
  • “These two studies presented at the prestigious AACR Annual Meeting are adding to the growing body of SP-3164 preclinical data demonstrating anticancer activity alone and in combination with standard-of-care treatments,” said David Arthur, president and chief executive officer of Salarius.
  • In addition, the data showed SP-3164 induced apoptosis in multiple myeloma cell lines.
  • In animal models, SP-3164 demonstrated superior single-agent activity compared to both lenalidomide (Revlimid®) and pomalidomide (Pomalyst®).

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 23, 2023
AACR, PM, Therapy, Non-Hodgkin lymphoma, Cancer, Immunity, FDIC, Research, Immunotherapy, Forecasting, Phases of clinical research, PacWest Bancorp, Section 46 of the Constitution of Australia, Section 24 of the Canadian Charter of Rights and Freedoms, Patient, AM, Jazz Pharmaceuticals, FDA, Pembrolizumab, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Tumor microenvironment, Food, Safety, Pharmaceutical industry, Vaccine

WATERTOWN, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • “Werewolf enters 2023 with considerable momentum following exceptional execution across our Company in 2022.
  • Financial Results for the Fourth Quarter and Full Year 2022:
    Cash position: As of December 31, 2022, cash and cash equivalents were $129.3 million, compared to $157.5 million as of December 31, 2021.
  • Net loss: Net loss was $11.9 million for the fourth quarter of 2022, compared to $17.9 million for the same period in 2021.
  • Net loss was $53.8 million for the full year 2022, compared to $50.0 million for the full year 2021.

Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

Retrieved on: 
Wednesday, March 22, 2023
Lymphoma, Pancreatic cancer, Marker, D, ARTEMIS, Data monitoring committee, Non-Hodgkin lymphoma, Food and Drug Administration, Clinical trial, Cell, HSCT, MRD, AML, Cancer, Patient, Polymerase chain reaction, Flow cytometry, Cytarabine, IND Culver Line, Research, FDA, Therapy, IND, Death, PCR, Hematopoietic stem cell transplantation, Food, Safety, Disease, Bone marrow, Pharmaceutical industry, Vaccine, Medical imaging, Nursing, Dentistry, Cryptocurrency

HOUSTON, March 22, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported fiscal year 2022 financial results and provided updates for its clinical development programs.

Key Points: 
  • Cash Position and Guidance: At December 31, 2022, Marker had cash and cash equivalents of $11.8 million.
  • R&D Expenses: Research and development expenses were $26.1 million for the year ended December 31, 2022, compared to $27.8 million for the year ended December 31, 2021.
  • G&A Expenses: General and administrative expenses were $12.8 million for the year ended December 31, 2022, compared to $12.9 million for the year ended December 31, 2021.
  • Net Loss: Marker reported a net loss of $29.9 million for the year ended December 31, 2022, compared to a net loss of $41.9 million for the year ended December 31, 2021.

Gamida Cell Announces Changes to Board of Directors

Retrieved on: 
Monday, March 20, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Gilead Sciences, University, Therapy, Parliamentary Information Technology Committee, Marketing, Chief commercial officer, Non-Hodgkin lymphoma, Audit committee, Shawn, MBA, Cell, Pharmacyclics, Acquisition, Patient, AbbVie, Kite Pharma, Cincinnati, Science and Technology Committee (House of Lords), Murray State University, Pharmaceutical industry

Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum.

Key Points: 
  • Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced the resignation of Chairman Robert I. Blum.
  • “On behalf of my fellow board members and Gamida Cell’s employees, I want to thank Robert for his dedicated service to this company,” said Abbey Jenkins, Gamida Cell President and Chief Executive Officer.
  • “Robert has been a tireless advocate for Gamida Cell for the past five years and has provided strong oversight through many critical decisions.
  • “Gamida Cell is at an inflection point, with the potential FDA approval of omidubicel in the near term.

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update

Retrieved on: 
Monday, March 20, 2023
Neuroblastoma, Male, Loss, CRS, Bank statement, Non-Hodgkin lymphoma, CMC, API, Clinical trial, Cancer, NKT, Research, Carboplatin, Chemistry, BCM, Acquisition, Patient, Investment, APD, Form, Viral, Baylor College of Medicine, PD-1, FDA, Death, IND, MHRA, Pharmaceutical industry, Dietary supplement, Cryptocurrency

Product sales for the full year 2022 were $90.9 million, up from $68.5 million in 2021, which represents a 33% increase.

Key Points: 
  • Product sales for the full year 2022 were $90.9 million, up from $68.5 million in 2021, which represents a 33% increase.
  • For further details on the Company’s financial results, including the results for the full year ended December 31, 2022, refer to the Form 10-K filed with the SEC.
  • As of December 31, 2022, the Company had cash and cash equivalents, restricted cash, and short-term investments of $36.7 million.
  • Athenex management will not host a conference call to accompany this release but intends to provide material updates when appropriate.

The Hemp Doctor Donates to Leukemia and Lymphoma Society

Retrieved on: 
Tuesday, March 14, 2023
American Foundation for the Blind, Cancer, B-cell lymphoma, Research, Hodgkin lymphoma, Quality of life, Lymphoma, Leukemia & Lymphoma Society, Hemp, Life, Organization, Patient, American Foundation for Suicide Prevention, American Cancer Society, Disease, Non-Hodgkin lymphoma, Multiple myeloma, CBD, Bone marrow, Hemp Industries Association, Pharmaceutical industry, Leukemia

Mooresville, North Carolina--(Newsfile Corp. - March 14, 2023) - On February 4, National Hemp Day, The Hemp Doctor raised $3,294.84 for the Leukemia and Lymphoma Society.

Key Points: 
  • Mooresville, North Carolina--(Newsfile Corp. - March 14, 2023) - On February 4, National Hemp Day, The Hemp Doctor raised $3,294.84 for the Leukemia and Lymphoma Society.
  • In 2020 Robert Shade, owner-operator of The Hemp Doctor was diagnosed with stage 4 non-Hodgkin's Lymphoma.
  • Donations to the Leukemia and Lymphoma Society was a way for the Shade family and The Hemp Doctor to say thank you for all the support they received through Robert's treatment and recovery.
  • In addition to this recent donation, the company donated $8,745 to the Leukemia and Lymphoma Society in June, 2021.

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

Retrieved on: 
Wednesday, March 15, 2023
AACR, Multiple myeloma, Cell death, Abstract, American Association for Cancer Research, NHL, Patient, Orange County Convention Center, Clinical trial, Non-Hodgkin lymphoma, Pharmaceutical industry

Both abstracts highlight preclinical activity with SP-3164, one focused on non-Hodgkin’s lymphoma (NHL) and the other on multiple myeloma (MM).

Key Points: 
  • Both abstracts highlight preclinical activity with SP-3164, one focused on non-Hodgkin’s lymphoma (NHL) and the other on multiple myeloma (MM).
  • Further assessment of SP-3164’s potential as a treatment for NHLs is warranted and a clinical trial is planned to start in 2023.
  • In multiple myeloma animal models, SP-3164 has superior single agent and combination treatment activity compared to approved molecular glues.
  • The abstracts were published yesterday afternoon and are now available on the AACR website at https://www.aacr.org .

Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute

Retrieved on: 
Wednesday, March 8, 2023
Society, Infrastructure as code, GVHD, Development, Bangladesh Technical Education Board, ASH, Epstein–Barr virus, Bone marrow, Graft-versus-host disease, Collaboration, Cell, Therapy, Safety, Gene editing, Research, Immune system, Cooperative research and development agreement, Baylor College of Medicine, Non-Hodgkin lymphoma, Patient, NCI, CTEP, Baylor University, CRADA, Risk, NIH, Pharmaceutical industry, Diagnosis

Tessa is currently advancing a Phase 1 clinical trial in the United States investigating TT11X in CD30-positive lymphomas.

Key Points: 
  • Tessa is currently advancing a Phase 1 clinical trial in the United States investigating TT11X in CD30-positive lymphomas.
  • “We are pleased to enter into a CRADA with NCI,” said Tessa President and CEO Thomas Willemsen.
  • Tessa plans to extend its allogeneic EBVST platform to other cancer indications, including solid tumors.
  • CD30.CAR-modified allogeneic EBVSTs without gene editing have demonstrated a strong safety profile and efficacy in early trials with minimal risk of graft-versus-host disease (GVHD).

Autolus Therapeutics Reports Full Year 2022 Financial Results and Operational Progress

Retrieved on: 
Tuesday, March 7, 2023
NHL, Follicular lymphoma, Therapy, GMP, CMC, Canadian Aviation Regulations, Multiple myeloma, Non-Hodgkin lymphoma, Patient, Good, EHA, European Hematology Association, B-ALL, CRS, MCL, MRD, Good manufacturing practice, Hand, Vii, Conference, Depreciation, Capital market, Employment, DLBCL, UCL, Exercise, Society, Information technology, Information, Conference call, Blackstone, CNS, CD19, ALL, Cancer, Research, Chronic lymphocytic leukemia, B-cell lymphoma, BLA, IDMC, CLL, Chemistry, Mantle cell lymphoma, ASH, GD2, FDA, Safety, CAR, Clinical trial, Data, BCMA, Nursing, Pharmaceutical industry, Cryptocurrency, Rare-earth element, Vaccine

Further details of the event will be provided in due course

Key Points: 
  • Further details of the event will be provided in due course
    LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the full year ended December 31, 2022.
  • The Company is evaluating patients across the entire range of disease burden, including patients with minimal residual disease (MRD).
  • Data presented at the European Hematology Association (EHA) meeting in June 2022 demonstrated first activity in primary CNS lymphoma.
  • Financial Results for the Year Ended December 31, 2022
    Cash and cash equivalents and restricted cash at December 31, 2022, totaled $382.8 million, as compared to $310.7 million at December 31, 2021.